Inactive Instrument

Analyst Reco. BioTime, Inc. Nyse

Equities

Baird Starts Lineage Cell Therapeutics at Outperform With $5 Price Target	22-11-02	MT
B. Riley Initiates Lineage Cell Therapeutics at Buy with $4 Price Target, Says Platform, Pipeline Currently Undervalued	22-06-14	MT
LINEAGE CELL THERAPEUTICS : Noble Capital Initiates Coverage on Lineage Cell Therapeutics With Outperform Rating, $8 Price Target	21-08-19	MT
LINEAGE CELL THERAPEUTICS : Chardan Suspends Coverage on Lineage Cell Therapeutics at Buy Rating With $4 Price Target	21-08-02	MT
LINEAGE CELL THERAPEUTICS : Cantor Fitzgerald Starts Lineage Cell Therapeutics at Overweight With $6 Price Target	21-03-31	MT

No results for this search